Most Recent Articles by Steve Duffy
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Patients who received concomitant NeP medications showed little difference in therapeutic response in comparison to those who received pregabalin alone.
The researchers graded their findings A, B, or C based on study quality.
The 6 mg dose will remain available.
Treatment with risperidone over a 6 month period was associated with an average weight gain of 5.4±3.4kg.
More Articles by Steve Duffy
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- The Handoff: Your Week in Neurology News - 3/23/17